The Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care: A Cross-Sectional Survey and Brief Intervention

Krupp, Joanna; Hung, Frances; Tucker, Tina; Yarrington, Michael E; Link, Katherine; Choi, Yujung; Chen, Hillary; Marais, Andrea C. Des; Sachdeva, Nidhi; Chakraborty, Hrishikesh; McKellar, Mehri

doi:10.2139/ssrn.4174117

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Including pharmacist-led collaborative care models for opioid use disorder is likely to be critical in addressing limits in prescriber capacity [42 ], however as the MAT Act does not include any mechanism to increase the number of pharmacies that offer OAT or address a lack of clarity around perceived ordering limits for OAT, concerns arise surrounding capacity of community pharmacies to keep up with an increased demand for OAT prescriptions [53]. Moreover, research examining the impact of prior policy changes, such as the removal of training requirements, suggest these may primarily influence behaviour among prescribers who are already moderately or highly interested in prescribing buprenorphine [54]. While removing unnecessary regulatory burdens is a critical step, emerging evidence suggests that additional interventions beyond removal of the waiver requirement may be needed to increase access [55].…”

Section: Discussionmentioning

confidence: 99%

Pharmacist-prescriber collaborative models of care for opioid use disorder: an overview of recent research

Cheetham,

Grist,

Nielsen

2024

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Purpose of review Collaborative models of care where pharmacists work alongside physicians have been developed for a range of physical health conditions, with benefits including improved patient outcomes and increased access to ongoing care. Opioid agonist treatment (methadone and buprenorphine) is a clinically effective and cost-effective treatment for opioid use disorder that is under-utilized in many countries due to a shortage of prescribers. In recent years, there has been increased interest in the development of collaborative models that utilize pharmacists to overcome barriers to treatment. In this article, we present a narrative review to synthesise recent work in this rapidly developing area. Recent findings Two key aspects of opioid agonist treatment were identified: Collaborative models have utilized pharmacists to facilitate buprenorphine induction, and collaborative models provide increased capacity for delivering ongoing care in a variety of settings and patient groups where prescriber access is limited. Pharmacists have undertaken direct patient care responsibilities with varying degrees of autonomy, with benefits including a reduction in prescriber workload, and improvements in treatment retention and continuity of care. Summary Collaborative models in which pharmacists are responsible for buprenorphine induction and ongoing management with methadone and buprenorphine have been shown to reduce demands on prescribers while improving or maintaining patient outcomes, and appear feasible and acceptable in a wide range of outpatient settings.

show abstract

Section: Discussionmentioning

confidence: 99%